GLENMARK PHARMACEUTICALS LTD.
BSE: 532296
values in crores
Revenue & Profit Trend
in croresRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|---|---|
| INCOME | ||||||
| Revenue | 2.4K+53.4% | 1.5K-35.8% | 2.4K+19.2% | 2.0K-10.7% | 2.3K-14.6% | 2.6K |
| Other Income | 109.06-61.8% | 285.76+312.1% | 69.33-21.6% | 88.45-31.5% | 129.19+55.5% | 83.08 |
| Total Income | 2.5K+35.3% | 1.8K-26.0% | 2.5K+17.5% | 2.1K-11.9% | 2.4K-12.5% | 2.7K |
| EXPENSES | ||||||
| Expenditure | 1.9K+8.1% | 1.8K+3.4% | 1.7K+0.1% | 1.7K-4.6% | 1.8K-5.4% | 1.9K |
| Tax | 64.46+138.6% | -167.18-335.7% | 70.94+112.4% | 33.40-77.1% | 145.69-27.2% | 200.00 |
| PROFIT | ||||||
| PBT | 346.53+138.2% | -906.37-325.9% | 401.17+121.4% | 181.16-67.6% | 559.49-29.6% | 795.06 |
| Net Profit | 282.07+138.2% | -739.19-323.8% | 330.23+123.5% | 147.76-64.3% | 413.80-30.5% | 595.06 |
| KEY METRICS | ||||||
| OPM % | 13.50%+85.63pp | -72.13%-89.04pp | 16.91%+8.88pp | 8.03%-8.26pp | 16.29%-8.19pp | 24.48% |
| NPM % | 11.42%+51.94pp | -40.52%-53.92pp | 13.40%+6.36pp | 7.04%-10.34pp | 17.38%-4.50pp | 21.88% |
| EPS | 10.00-61.8% | 26.19+123.8% | 11.70+123.3% | 5.24-64.3% | 14.66-30.5% | 21.09 |
Corporate Events
Board MeetingGLENMARK
202629May
Board Meeting
The Board of Directors will meet to consider and approve the…
BSE Filing ↗ Board MeetingGLENMARK
202414Nov
Board Meeting
Consider and approve the Unaudited Financial Results
BSE Filing ↗ Board MeetingGLENMARK
202424May
Board Meeting
Consider and approve the Standalone and Consolidated Audited…
BSE Filing ↗ Board MeetingGLENMARK
202310Nov
Board Meeting
Consider and approve Unaudited Financial Results for the sec…
BSE Filing ↗ Board MeetingGLENMARK
20235Oct
Board Meeting
Consider and approve the Sale of Equity Shares of Glenmark L…
BSE Filing ↗ Board MeetingGLENMARK
202311Aug
Board Meeting
Consider and approve Unaudited Financial Results for the Fir…
BSE Filing ↗